United Front Intl
No Result
View All Result
Tuesday, February 7, 2023
  • Login
  • Register
  • Home
  • US
  • World
  • Politics
  • Coronavirus
  • Videos
  • Be in the Know
  • ShopNew
Contact us
United Front Intl
  • Home
  • US
  • World
  • Politics
  • Coronavirus
  • Videos
  • Be in the Know
  • ShopNew

No products in the cart.

No Result
View All Result
United Front Intl
No Result
View All Result
Home Coronavirus

What to know about booster shots if you received Johnson & Johnson’s COVID-19 vaccine

by admin
September 12, 2021
in Coronavirus
What to know about booster shots if you received Johnson & Johnson’s COVID-19 vaccine

FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Share on FacebookShare on Twitter

PBS
By Maureen Ferran

For people who received the Johnson & Johnson COVID-19 vaccine, the past few months have been a bit of a bumpy ride with news of side effects, pauses and restarts and now boosters. Maureen Ferran is a virologist at the Rochester Institute of Technology and has been keeping tabs on the Johnson & Johnson vaccine. Six months after the vaccine first received emergency use authorization, Ferran explains the latest research regarding its effectiveness, boosters and waning immunity against the delta variant.

How many people in the U.S. received the Johnson & Johnson vaccine?
As of late August 2021, 14 million Americans had received the Johnson & Johnson COVID-19 vaccine. This accounts for a little over 8% of the 170.8 million Americans who are fully vaccinated, the rest of whom received a Pfizer or Moderna mRNA vaccine.

How effective has it proved to be?
Clinical trial data showed that four weeks after vaccination, the Johnson & Johnson vaccine was 66.3% effective at preventing COVID-19 infection. The initial studies also showed that it was 85% effective at preventing severe disease and 100% effective at protecting against COVID-related hospitalization.

Many studies are underway to evaluate how well the various COVID-19 vaccines perform in the real world. Though most have focused on the Pfizer and Moderna vaccines, one study that has yet to be peer–reviewed looked at the Johnson & Johnson vaccine and found it to be 76.7% effective at preventing infection among vaccinated individuals – slightly better than the clinical trials.

But the original clinical trials and most subsequent studies were done before the delta variant became responsible for almost all of the COVID-19 cases in the U.S. Early studies suggest that although COVID-19 vaccines are still effective against this variant, in general their efficacy is lower compared to protection against the original strain. In early August 2021, the South African government released data showing that against the delta variant, the Johnson & Johnson vaccine provides 65% to 66% protection against hospitalization and 91% to 95% protection against death. This lower efficacy against delta means some fully vaccinated individuals will get infected. But of those that do, less than 0.1% face hospitalization or death.

How long does protective immunity last?
The amount of “neutralizing antibodies” in a person – antibodies that defend a cell from the coronavirus – is an accurate measure of protection within the first several months after vaccination. Studies show that individuals who received a Johnson & Johnson or an mRNA vaccine continue to produce antibodies for at least six months after vaccination. However, neutralizing antibody levels start to wane over time.

This may sound bad, but it isn’t clear that lower antibody levels correlates with an increased risk of severe infection. Antibody levels normally decline over time. The immune system’s long-term surveillance is done by “memory” immune cells that will prevent or reduce disease severity if a person is exposed to the virus at a later time.

More studies are needed to determine the role of memory cells in protection against the virus, and scientists are collecting real-world data from vaccinated people to determine when they may become vulnerable to infection again.

Do Johnson & Johnson recipients need a booster shot?
Many countries, including the U.S., are considering the need for booster shots, but many scientists believe more data is needed before making a decision.

Some worry that giving boosters to people in wealthy nations will waste precious doses that could be given to unvaccinated people in poorer countries. To prevent this, the World Health Organization called for a moratorium on boosters until at least the end of September.

On Aug. 25, 2021, Johnson & Johnson announced that people who initially received a single shot vaccine and then received the same shot as a booster produced a much stronger antibody response than after receiving a single dose. This new study provides data to support a booster for those who received the single-dose Johnson & Johnson vaccine despite the larger controversy and uncertainty.

On Aug. 22, 2021, U.S. Surgeon General Dr. Vivek Murthy said that Johnson & Johnson recipients will “likely need a booster.” The government needs more information before making a recommendation about the need for a booster shot, and since the vaccine was rolled out three months after the mRNA vaccines, key studies are still in progress.

One important question is whether someone who received the Johnson & Johnson shot should get a second Johnson & Johnson dose or mix and match – get a second dose of a different vaccine.

What about the side effects?
The vast majority of vaccines – including the Johnson & Johnson and mRNA vaccines – produce common side effects such as pain at the injection site, headache, fatigue, muscle and joint pain, chills and fever.

In early April 2021, the Food and Drug Administration and Centers for Disease Control and Prevention recommended a pause on the Johnson & Johnson vaccine because of reports of rare allergic reactions and increased risk of certain types of rare blood clots, as well as Guillian-Barré Syndrome, a very rare disorder in which an individual’s immune system damages their own nerves.

The agencies lifted the pause on April 23 after a review found that serious side effects are very rare – the blood clots occur at a rate of about seven cases per million doses in women between the ages of 18 and 49, with much lower rates in other people. Overall, the CDC determined that the benefits of these vaccines far outweigh the risks.

A recent CDC study showed that unvaccinated people are almost five times more likely to be infected by the coronavirus and 29 times more likely to be hospitalized with COVID-19 compared to fully vaccinated individuals. Therefore, all the evidence suggests that the millions of Americans who are able to get vaccinated but are choosing not to are putting themselves – and others – at serious risk.

This article is republished from The Conversation under a Creative Commons license.
Editor’s note: Johnson & Johnson is a funder for the PBS NewsHour.
By — Maureen Ferran, The Conversation
Maureen Ferran is an associate professor of biology at Rochester Institute of Technology.

Related

ShareTweetSendSend

Related Posts

What is known about new Covid variant XBB.1.5?
Coronavirus

What is known about new Covid variant XBB.1.5?

January 17, 2023
Explainer: COVID, flu and RSV this U.S. winter: Why experts are worried
Coronavirus

Explainer: COVID, flu and RSV this U.S. winter: Why experts are worried

October 27, 2022
Moderna seeks to be 1st with COVID shots for littlest kids
Coronavirus

Moderna seeks to be 1st with COVID shots for littlest kids

April 28, 2022
The Biden administration says it may appeal a ruling that voided a mask mandate on public transport.
Coronavirus

The Biden administration says it may appeal a ruling that voided a mask mandate on public transport.

April 19, 2022
Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds
Coronavirus

Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds

March 30, 2022
U.S. authorizes second COVID booster for Americans 50 and older
Coronavirus

U.S. authorizes second COVID booster for Americans 50 and older

March 29, 2022

My Cart

No Content Available

Categories

  • Be in the Know
  • Coronavirus
  • Politics
  • US
  • Videos
  • World

UnitedFrontIntl Store

My Account & Ordering
Cart
Checkout
Track My Order
Refund and Returns Policy
Privacy Policy
FAQs

Site Navigation

  • Home
  • Advertise
  • Contact Us
  • Jobs
  • About Us
  • Shipping Policy

Links

CNBC
Reuters

The New York Times
The Washington Post


Your tax-deductible gift is vital and will help us fund and maintain our website to bring you current news and information on a daily basis. Thank you in advance.

© 2022 United Front Intl

No Result
View All Result
  • Home
  • US
  • World
  • Politics
  • Coronavirus
  • Videos
  • Be in the Know
  • Contact Us
  • Advertisement
  • Shop

© 2022 United Front Intl

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In